When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
OVID - Ovid Advances Fragile X Syndrome Drug Forward; Multiple Catalysts Still Expected In 2020
Ovid Therapeutics Inc.
Ovid Therapeutics (OVID) announced that it had achieved positive resultsfrom a Phase 2 study using its drug OV101 to treat patients with Fragile X Syndrome. With this news in hand, that sets up an opportunity for the biotech to meet with the FDA in the coming months in a meeting. This sets up a catalyst opportunity in that a Phase 3 study may be initiated based on this positive data. Besides this data in Fragile X Syndrome, a more advanced indication being targeted in the pipeline includes another disease known as Angelman